NCT00078000
Completed
Phase 2
A Phase 2 Study Of The Efficacy And Safety Of SU011248 In Patients With Metastatic Breast Cancer
ConditionsBreast Neoplasms
DrugsSU011248
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Breast Neoplasms
- Sponsor
- Pfizer
- Enrollment
- 64
- Locations
- 1
- Primary Endpoint
- Anti-tumor efficacy
- Status
- Completed
- Last Updated
- 17 years ago
Overview
Brief Summary
Assessment of safety and efficacy of SU11248 in patients with metastatic breast cancer who have failed selected other therapies.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Anthracycline and taxane-refractory or intolerant metastatic breast cancer
Exclusion Criteria
- •Prior treatment with 3 or greater regimens of chemotherapy in the advanced/metastatic disease setting beyond those containing anthracyclines/taxanes.
Outcomes
Primary Outcomes
Anti-tumor efficacy
Secondary Outcomes
- Tumor control survival safety pharmacokinetics
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
Treatment With SU11248 in Patients With Neuroendocrine TumorsNeuroendocrine TumorsNCT00056693Pfizer107
Completed
Phase 2
Assessment Of Safety And Efficacy Of SU11248 In Patients With Metastatic Colorectal Cancer Who Have Failed Selected Previous Treatments.Colorectal NeoplasmsNCT00077987Pfizer84
Completed
Phase 2
Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung CancerCarcinoma, Non-Small-Cell LungNCT00092001Pfizer111
Terminated
Phase 2
Efficacy of SU 011248 in Head And Neck CarcinomaRecurrent DiseaseSquamous Cell Head and Neck CarcinomaPalliative TreatmentNCT00408252Cliniques universitaires Saint-Luc- Université Catholique de Louvain54
Completed
Phase 2
Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain MetastasesNon-Small Cell Lung CancerNCT00372775Pfizer66